Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Hepatology

• Publication date

  2010-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.23778PMID 20593455PMCID PMC3086357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiviral antibody responses: the two extremes of a wide spectrum

  2006cited by this paper
• Immunology of hepatitis B virus and hepatitis C virus infection

  2005cited by this paper
• Medicinal chemistry: Best of both worlds?

  2005cited by this paper
• Hepatitis B viral kinetics: A dynamic puzzle still to be resolved

  2005cited by this paper
• A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative

  2005cited by this paper
• Hepatitis B virus infection--natural history and clinical consequences.

  2004cited by this paper
• Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1

  2004cited by this paper
• Endocytosis of Hepatitis B Immune Globulin into Hepatocytes Inhibits the Secretion of Hepatitis B Virus Surface Antigen and Virions

  2003cited by this paper
• A 'first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of 'second loop' immune escape.

  2003cited by this paper
• HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis

  2003cited by this paper
• The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine.

  2002cited by this paper
• Antibodies, viruses and vaccines

  2002cited by this paper
• Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties

  2002cited by this paper
• Antibody-induced internalization of viral glycoproteins in pseudorabies virus-infected monocytes and role of the cytoskeleton: a confocal study.

  2002cited by this paper
• Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination

  2001cited by this paper
• Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

  2001cited by this paper
• Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

  2001cited by this paper
• Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed

  2001cited by this paper
• Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

  2000cited by this paper
• Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

  2000cited by this paper
• Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review

  2000cited by this paper
• Preclinical Evaluation of Two Human Anti–Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV‐Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees

  2000cited by this paper
• A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site

  1999cited by this paper
• Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

  1999cited by this paper
• Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system

  1998influential reference
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies

  1995cited by this paper
• The serology of chronic hepatitis B infection revisited.

  1993cited by this paper
• Antibody-mediated clearance of alphavirus infection from neurons.

  1991cited by this paper
• Production of monoclonal antibodies to hepatitis B surface and core antigens, and use in the detection of viral antigens in liver biopsies

  1983cited by this paper
• Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies

  1983cited by this paper
• Nondetection of infectious hepatitis B virus in a human hepatoma cell line producing hepatitis B surface antigen.

  1981influential reference
• PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity

  1980cited by this paper
• Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line

  1979cited by this paper
• Polypeptides of hepatitis B virus surface antigen produced by a hepatoma cell line

  1979cited by this paper
• Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell

  1979cited by this paper
• Hepatitis B surface antigen produced by a human hepatoma cell line

  1979cited by this paper
• Establishment of a continuously growing cell line from primary carcinoma of the liver.

  1976cited by this paper

• Targeting HBV with RNA interference: Paths to cure.

  2025cites this paper
• Investigation of a two-patch within-host model of hepatitis B viral infection

  2025cites this paper
• A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions

  2025cites this paper
• Investigation of a Two-Patch Within-Host Model of Hepatitis B Viral Infection

  2025cites this paper
• The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus

  2025cites this paper
• Modeling of hepatitis B virus infection spread in primary human hepatocytes

  2025cites this paper
• Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine

  2025cites this paper
• Modeling of hepatitis B virus infection spread in primary human hepatocytes

  2025cites this paper
• Achieving Global Immunity Against Hepatitis A through Universal Vaccination: A Position Paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis (ESGVH).

  2025cites this paper
• HepB-CpG vaccination: An alternate strategy to life long antiviral therapy in patients transplanted for chronic Hepatitis B.

  2025cites this paper
• HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study.

  2024cites this paper
• Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure

  2024cites this paper
• Inherent symmetry and flexibility in hepatitis B virus subviral particles

  2024cites this paper
• Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers

  2024cites this paper
• Mathematical Models of Early Hepatitis B Virus Dynamics in Humanized Mice

  2024cites this paper
• Hepatitis delta: epidemiology to recent advances in therapeutic agents.

  2023cites this paper
• Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion

  2023cites this paper
• Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation for analyzing extracellular viral markers

  2023cites this paper
• Novel therapeutic strategies for chronic hepatitis B

  2022cites this paper
• A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

  2022cites this paper
• Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus

  2022cites this paper
• Recent Advances in Hepatitis B Treatment

  2021cites this paper
• Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

  2021cites this paper
• Immunopathogenesis of Hepatitis B Virus Infection

  2021cites this paper
• Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants

  2021cites this paper
• Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

  2021cites this paper
• Immunobiology and pathogenesis of hepatitis B virus infection

  2021cites this paper
• Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?

  2021cites this paper
• Efficient Methods for Parameter Estimation of Ordinary and Partial Differential Equation Models of Viral Hepatitis Kinetics

  2020cites this paper
• Direct-acting antivirals and viral RNA targeting for hepatitis B cure.

  2020cites this paper
• Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg

  2020cites this paper
• Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection

  2020cites this paper
• Stochastic analysis of in-host HCV dynamics through budding and bursting process

  2020cites this paper
• Understanding the antiviral effects of RNAi-based therapy on chronic hepatitis B infection

  2020cites this paper
• The role of hepatitis B surface antibodies in HBV infection, disease and clearance

  2020cites this paper
• Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load

  2019cites this paper
• Liver chimeric mice with tupaia hepatocyte transplantation as an animal model for hepatitis B virus infection and antiviral therapy

  2019cites this paper
• Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications.

  2019cites this paper
• Defective circulating and intrahepatic B cells in chronic HBV

  2019cites this paper
• Within-host mathematical models of hepatitis B virus infection: Past, present, and future.

  2019cites this paper
• HBV antigen and DNA loss from mouse serum is associated with novel vaccine‐induced HBV surface antigen‐specific cell‐mediated immunity and cytokine production

  2019cites this paper
• An E. coli‐produced single‐chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion

  2019cites this paper
• A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics

  2019cites this paper
• Therapeutic strategies for hepatitis B virus infection: towards a cure

  2019cites this paper
• Restoring, releasing or replacing adaptive immunity in chronic hepatitis B

  2019cites this paper
• Viral envelope-specific antibodies in chronic hepatitis B virus infection.

  2018cites this paper
• Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience.

  2018cites this paper
• HCVMultiscaleDyn: A simulator for the multiscale model of hepatitis C virus dynamics

  2018cites this paper
• Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

  2018cites this paper
• HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis

  2018cites this paper
• A potent human neutralizing antibody Fc-dependently reduces established HBV infections

  2017cites this paper
• A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics

  2017cites this paper
• Mathematical Modeling as a Tool to Elucidate HCV Infection Kinetics and Treatment Response

  2017cites this paper
• Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.

  2017cites this paper
• Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg

  2017cites this paper
• In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy

  2017cites this paper
• Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals

  2016cites this paper
• Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B

  2015cites this paper
• Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

  2015cites this paper
• Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection

  2015cites this paper
• Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence

  2015cites this paper
• A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal

  2015cites this paper
• Adaptive Immunity and Inflammation

  2015cites this paper
• HBV Disease Spectrum and OBI

  2015cites this paper
• Hepatitis B virus replication and integration

  2014cites this paper
• Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling

  2014cites this paper
• Contradictory Immune Response in Post Liver Transplantation Hepatitis B and C

  2014cites this paper
• Safe and cost-effective control of post-transplantation recurrence of hepatitis B

  2014cites this paper
• Use of HBSAG Quantification To Guide HBIG Prophylaxis After Liver Transplantation

  2014cites this paper
• Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test

  2014cites this paper
• Infection Theiler Murine Encephalomyelitis Virus Modeling the Acute and Chronic Phases of

  2013influential citation
• A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity

  2013cites this paper
• High incidence of treatment‐induced and vaccine‐escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B–infected patients

  2013cites this paper
• Modeling the Acute and Chronic Phases of Theiler Murine Encephalomyelitis Virus Infection

  2013influential citation
• Molecular Mechanisms Underlying Occult Hepatitis B Virus Infection

  2012cites this paper
• Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.

  2012cites this paper
• Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise

  2012cites this paper
• Modeling of Viral Dynamics after Liver Transplantation in Patients with Chronic Hepatitis B and D

  2012cites this paper
• Respiratory syncytial virus vaccine development

  2011cites this paper
• The life cycle of hepatitis B virus and antiviral targets

  2011cites this paper
• Pathogen and autoantigen homologous regions within the cystic fibrosis transmembrane conductance regulator (CFTR) protein suggest an autoimmune treatable component of cystic fibrosis.

  2011cites this paper
• Bioinformatics analysis of homologies between pathogen antigens, autoantigens and the CFTR cystic fibrosis protein: A role for immunoadsorption therapy?

  2010cites this paper